Applied DNA Sciences shifts focus to genetic medicines, selling assets and cutting costs.

Applied DNA Sciences has announced a strategic shift to focus on producing essential materials for genetic medicines. The company plans to sell its CertainT platform, reduce operating expenses by 15%, and keep Applied DNA Clinical Labs for its profitable pharmacogenomic testing services. The completion of its GMP manufacturing facility is expected by January 9, 2025, with potential annual revenue of $4 million to $16 million.

3 months ago
5 Articles